Actos Needs Stronger Cancer Warnings: EU Regulator

Law360, New York (July 25, 2011, 4:04 PM EDT) -- European health regulators said Thursday that Takeda Pharmaceutical Co. Ltd.'s diabetes drug Actos — which has been banned in France and Germany — remains a valid treatment option, but should come with stronger warnings about its increased risk of bladder cancer.

In the findings of its review of pioglitazone-containing medicines and the occurrence of bladder cancer, the European Medicines Agency's Committee for Medicinal Products for Human Use concluded that the benefits of the drugs outweigh the risks for certain patients with Type 2 diabetes.

The committee...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.